Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 4/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27420807 | 0.98 | TP53 (0.52) | TP53OPRM1CA1SPHK1LAP3 | |
| SCHEMBL14642186 | 0.98 | TP53 (0.52) | TP53OPRM1CA1SPHK1LAP3 | |
| SCHEMBL6113068 | 0.93 | TP53 (0.45) | TP53OPRM1CA1SPHK1FDPS | |
| SCHEMBL457712 | 0.82 | — | — | |
| SCHEMBL14967061 | 0.80 | TP53 (0.58) | TP53OPRM1CA1SPHK1LAP3 | |
| SCHEMBL9662687 | 0.78 | TP53 (0.56) | TP53OPRM1CA1SPHK1LAP3 | |
| SCHEMBL8814042 | 0.78 | TP53 (0.56) | TP53OPRM1CA1SPHK1LAP3 | |
| SCHEMBL2489859 | 0.76 | TP53 (0.59) | TP53OPRM1CA1SPHK1LAP3 | |
| SCHEMBL7864585 | 0.76 | TP53 (0.43) | TP53FDPSCA2GPR84FFAR1 | |
| SCHEMBL3664636 | 0.76 | TP53 (0.43) | TP53CA1FDPSCA2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112830893-A | ROR gamma inhibitor, preparation method and medical application thereof | 成都倍特药业股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-106543189-A | A kind of dipeptidyl peptidase-iv inhibitor | 成都硕鼎科技有限公司 | 2017-03-29 | — | — | CN | disclosed |
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
| EP-1606248-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080951-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
| EP-1457485-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | TP53 2254/4885OPRM1 1356/4885CA1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.